Patients were categorized into three subgroups: patients with G1 tumours with a Ki‐67 index of 10 per cent or less (group 1); patients with G3 tumours with a Ki‐67 index above 50 per cent (group 2); all other patients (those with G1 tumours with a Ki‐67 index above 10 per cent, G2 tumours with any Ki‐67 index value and G3 tumours with a Ki‐67 index of 50 per cent or less) (group 3) (Fig. 3). This evidence concerns the gene MKI67 and neoplasm.